Martini C H, Brandts A, de Bruijne E L E, van Hylckama Vlieg A, Leebeek F W G, Lisman T, Rosendaal F R
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Br J Haematol. 2006 Jul;134(1):92-4. doi: 10.1111/j.1365-2141.2006.06117.x.
Thrombin activatable fibrinolysis inhibitor (TAFI) is an important inhibitor of fibrinolysis. High TAFI antigen levels are associated with an increased risk of deep venous thrombosis (DVT). Because TAFI levels are partly determined genetically, we assessed the association between three TAFI gene polymorphisms (-438 G/A, 505 A/G and 1040 C/T), TAFI antigen levels and clot lysis times and the risk of DVT. Carriers of the 505G allele, which is associated with lower TAFI antigen levels than the 505A allele, showed an increased risk of DVT. This indicates that the relationship between TAFI and venous thrombosis is more complex than previously suggested.
凝血酶激活的纤维蛋白溶解抑制剂（TAFI）是一种重要的纤维蛋白溶解抑制剂。TAFI抗原水平升高与深静脉血栓形成（DVT）风险增加相关。由于TAFI水平部分由遗传决定，我们评估了三种TAFI基因多态性（-438 G/A、505 A/G和1040 C/T）、TAFI抗原水平和血块溶解时间与DVT风险之间的关联。与505A等位基因相比，505G等位基因携带者的TAFI抗原水平较低，其DVT风险增加。这表明TAFI与静脉血栓形成之间的关系比之前认为的更为复杂。
